[go: up one dir, main page]

PT2909204T - Inibidores de gsk3 e métodos de utilização dos mesmos - Google Patents

Inibidores de gsk3 e métodos de utilização dos mesmos

Info

Publication number
PT2909204T
PT2909204T PT13780300T PT13780300T PT2909204T PT 2909204 T PT2909204 T PT 2909204T PT 13780300 T PT13780300 T PT 13780300T PT 13780300 T PT13780300 T PT 13780300T PT 2909204 T PT2909204 T PT 2909204T
Authority
PT
Portugal
Prior art keywords
methods
gsk3 inhibitors
gsk3
inhibitors
Prior art date
Application number
PT13780300T
Other languages
English (en)
Inventor
B Holson Edward
Fevrier Wagner Florence
Q Pan Jennifer
Dandapani Sivaraman
Germain Andrew
Munoz Benito
P Nag Partha
Weiwer Michel
C Lewis Michael
J Haggarty Stephen
A Bishop Joshua
Stegmaier Kimberly
Banerji Versha
Original Assignee
Dana Farber Cancer Inst Inc
Massachusetts Gen Hospital
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Massachusetts Gen Hospital, Broad Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of PT2909204T publication Critical patent/PT2909204T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT13780300T 2012-10-12 2013-10-11 Inibidores de gsk3 e métodos de utilização dos mesmos PT2909204T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713314P 2012-10-12 2012-10-12
US201361779394P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
PT2909204T true PT2909204T (pt) 2019-03-21

Family

ID=49474737

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13780300T PT2909204T (pt) 2012-10-12 2013-10-11 Inibidores de gsk3 e métodos de utilização dos mesmos

Country Status (16)

Country Link
US (4) US9096594B2 (pt)
EP (1) EP2909204B1 (pt)
JP (2) JP6321662B2 (pt)
CA (1) CA2887701C (pt)
CY (1) CY1122601T1 (pt)
DK (1) DK2909204T3 (pt)
ES (1) ES2719776T3 (pt)
HR (1) HRP20190406T1 (pt)
HU (1) HUE043853T2 (pt)
LT (1) LT2909204T (pt)
PL (1) PL2909204T3 (pt)
PT (1) PT2909204T (pt)
RS (1) RS58700B1 (pt)
SI (1) SI2909204T1 (pt)
SM (1) SMT201900136T1 (pt)
WO (1) WO2014059383A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900136T1 (it) 2012-10-12 2019-05-10 Massachusetts Gen Hospital Inibitori di gsk3 e loro metodi di uso
SMT202000223T1 (it) 2013-03-14 2020-05-08 Brigham & Womens Hospital Inc Composizioni e metodi per l'espansione e la coltura di cellule staminali epiteliali
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
JP6773645B2 (ja) 2014-09-03 2020-10-21 ザ ブリガム アンド ウィミンズ ホスピタル，インコーポレイテッド 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法
WO2016061344A1 (en) * 2014-10-15 2016-04-21 Mirx Pharmaceuticals Llc Gsk3 inhibitors and their uses
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
JP7109446B2 (ja) 2016-12-30 2022-07-29 フリークエンシー セラピューティクス インコーポレイテッド 幹細胞／前駆支持細胞の自己複製を誘導するための１ｈ－ピロール－２，５－ジオン化合物およびその使用方法
CA3058198A1 (en) * 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
CN110407769B (zh) * 2018-04-27 2022-11-08 复旦大学 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途
CN117883438A (zh) 2018-06-05 2024-04-16 开动疗法公司 治疗恶性淋巴增生性疾病的方法
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2021102305A1 (en) * 2019-11-20 2021-05-27 Washington University Methods and compositions for generating functionally mature beta cells and uses thereof
WO2023056463A1 (en) * 2021-09-30 2023-04-06 Trustees Of Tufts College Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome
EP4601637A2 (en) * 2022-10-13 2025-08-20 The Broad Institute Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024259178A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
JPH08509713A (ja) 1993-04-08 1996-10-15 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 認識疾患の治療に有用な神経伝達物質放出増強剤としての新規な多環式系およびその誘導体
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
KR20030076650A (ko) 2001-02-02 2003-09-26 미쯔비시 웰 파마 가부시키가이샤 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
CA2450167A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
CN1823067A (zh) * 2003-06-13 2006-08-23 赞塔里斯有限公司 具有抑制磷脂酰肌醇3－激酶活性的化合物及其使用方法
PT1746097E (pt) * 2005-07-20 2010-04-15 Aventis Pharma Sa Heterociclos fundidos de 1,4-di-hidropiridina, processo para a sua preparação, utilização e composições que os contêm
WO2008016123A1 (fr) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US9265764B2 (en) 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
SMT201900136T1 (it) * 2012-10-12 2019-05-10 Massachusetts Gen Hospital Inibitori di gsk3 e loro metodi di uso
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2014139870A (ja) * 2013-01-21 2014-07-31 Hitachi Consumer Electronics Co Ltd 照明装置およびこれを用いた映像表示装置
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
US10437707B2 (en) * 2015-03-19 2019-10-08 Teachers Insurance And Annuity Association Of America Evaluating and presenting software testing project status indicators
CA3058198A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Also Published As

Publication number Publication date
US20220160702A1 (en) 2022-05-26
US20190175584A1 (en) 2019-06-13
US20140107141A1 (en) 2014-04-17
JP2018150302A (ja) 2018-09-27
US11052080B2 (en) 2021-07-06
DK2909204T3 (en) 2019-04-01
US20150313890A1 (en) 2015-11-05
CY1122601T1 (el) 2021-03-12
WO2014059383A1 (en) 2014-04-17
ES2719776T3 (es) 2019-07-16
CA2887701A1 (en) 2014-04-17
JP6321662B2 (ja) 2018-05-09
US12419885B2 (en) 2025-09-23
US10137122B2 (en) 2018-11-27
SMT201900136T1 (it) 2019-05-10
JP2015536307A (ja) 2015-12-21
LT2909204T (lt) 2019-05-10
US9096594B2 (en) 2015-08-04
JP6606691B2 (ja) 2019-11-20
RS58700B1 (sr) 2019-06-28
US20200061050A9 (en) 2020-02-27
PL2909204T3 (pl) 2019-07-31
HUE043853T2 (hu) 2019-09-30
CA2887701C (en) 2020-12-15
SI2909204T1 (sl) 2019-06-28
HRP20190406T1 (hr) 2019-05-31
EP2909204B1 (en) 2018-12-05
EP2909204A1 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
PT2909204T (pt) Inibidores de gsk3 e métodos de utilização dos mesmos
CY2022018I1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
IL244488A0 (en) Inhibitors of erk and methods of use
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
BR112013029163A2 (pt) modulação quinase e indicações dos mesmos
KR102096014B9 (ko) PCSK9 iRNA 조성물 및 그 사용 방법
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
IL235401A0 (en) St2l antagonists and methods of use
CL2015000640A1 (es) Variantes de hppd y métodos de uso
DK2920168T3 (da) Heterocykliske glutaminase-inhibitorer
BR112014030410A2 (pt) inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
BR112015002090A2 (pt) placa de laser e amplificador e método de uso
BR112013033098A2 (pt) inibidores de glicosidade seletivos e usos dos mesmos
HUE037444T2 (hu) ACC inhibitorok és azok felhasználása
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
RS55690B1 (sr) So inhibitora ljudske histonske metiltransferaze ezh2
BR112013013167A2 (pt) inibidores de bromodomínio e usos dos mesmos
EP2890679A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
BR112014009006A2 (pt) compostos heterocíclicos e métodos de uso dos mesmos
CL2016000235A1 (es) Inhibidores de rorc2 y sus métodos de uso
IL229767A0 (en) Glioblastoma inhibiting compounds and their use
DK2841684T3 (da) Oliefeltanordning og fremgangsmåde til anvendelse
DK2827883T3 (da) Tfpi-inhibitorer og fremgangsmåder til anvendelse
EP2858975A4 (en) FBXO3 INHIBITORS
IL235909A0 (en) Heteroaryl compounds and methods of use thereof